• Jiabing Zhu, Banhe Ding, and Yufeng Li.
• Department of Hematology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, P R China.
• Leuk. Lymphoma. 2013 Jul 1; 54 (7): 1426-9.

AbstractTo evaluate the efficacy of interferon-α (IFN-α) combined with homoharringtonine (HHT) in the treatment of patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CML), an IFN-α combined with HHT scheme was used as induction and maintenance therapy for 42 patients with CML in chronic phase. Thirty-five patients treated with IFN-α alone were used as the control group. It was found that the cytogenetic response rate and estimated 2-year survival rate were higher in the IFN-α + HHT group than in the IFN-α group (52.4% vs. 28.6% and 90% vs. 73%, respectively). No grade 3 or 4 hematological toxicity, severe infections, hemorrhage or non-hematological adverse reactions were observed. From this research it can be concluded that an IFN-α combined with HHT scheme is safe and effective for CML induction and long-term maintenance therapy. It may be a good choice for patients with CML who cannot accept a hematopoietic stem cell transplant and imatinib or who fail IFN-α therapy.

19 keywords...

hide…